Get to know our clinical trials

Clinical trial to evaluate the efficacy and safety of adjuvant Giredestrant compared to physician-choice adjuvant endocrine monotherapy in patients with estrogen receptor-positive, HER2-negative early breast cancer.

THE PURPOSE OF THIS STUDY IS TO COMPARE THE EFFECTS, POSITIVE OR NEGATIVE, OF GIREDESTRANT WITH THOSE OF AN APPROVED ENDOCRINE TREATMENT (TREATMENT THAT BLOCKS OR REMOVES HORMONES) IN PATIENTS WITH YOUR TYPE OF CANCER. IN THIS STUDY YOU WILL RECEIVE GIREDESTRANT OR A DRUG CHOSEN SPECIFICALLY FOR YOU BY THE STUDY DOCTOR.

Status
In recruitment
headquarters
Pamplona

Technical Summary

  • PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED TO PHYSICIAN-CHOICE ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER.
  • Code EudraCT: 2021-000129-28
  • Protocol number: GO42784
  • Promoter: Hoffman La Roche
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.